UNION PACIFIC CORP

Union Pacific’s latest report shows steady earnings, rising freight volumes and a $X million rail‑upgrade plan that boosts reliability, safety and shareholder value.

Union Pacific Corp pivots to biotech, buying a Santa Cruz firm for $1 billion to tap macrocyclic peptide drugs for immune‑mediated disorders.

Union Pacific officers buy shares under its 2021 ESPP, signaling modest confidence and highlighting governance, market impact and future railroad strategy.